To incorporate these ideas and findings in the context of AML and other blood cancers, we tested a variety of bispecific constructs targeting CD33, CD16b and other blood-related antigens (Figures 5, 6A). Here, CD33 is linked to hematopoietic and lymphoid system neoplasm.